Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: A prospective observational study

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Solá, Montserrat ^a   Margelí, Mireia ^a   Castellá, Eva ^a   Julian, Juan F ^a   Rull, Miquel ^a   Gubern, Josep M ^b   Mariscal, Antonio ^a   Barnadas, Agustí ^a   Fraile, Manuel ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Mataro Hospital   (Spain)

Author keywords

Bone marrow; Breast cancer; Disseminated tumor cells; Sentinel node; Survival

Indexed keywords

ALBUMIN TC 99M COLLOID; CYTOKERATIN ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BONE MARROW BIOPSY; BONE MARROW METASTASIS; BREAST CARCINOMA; BREAST SURGERY; CANCER CLASSIFICATION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; EARLY CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; ILIAC CREST; IMMUNOCYTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHOSCINTIGRAPHY; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; MORBIDITY; OBSERVATIONAL STUDY; PROGNOSIS; PROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; TRIPLE NEGATIVE BREAST CANCER; ADJUVANT CHEMOTHERAPY; AXILLA; BLOOD; BONE MARROW; BREAST TUMOR; CARCINOMA; CLINICAL TRIAL; FEMALE; MASTECTOMY; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SCINTISCANNING; SURVIVAL; TREATMENT OUTCOME; TUMOR EMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BONE MARROW; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79959200388     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-252     Document Type: Article

References (36)

1. Pollán M, Michelena MJ, Ardanaz E, Izquierdo A, Sánchez-Pérez MJ, Torrella A. Breast cancer incidence in Spain before, during and after the implementation of screening programmes. Ann Oncol 2010, 21(Suppl 3):97-102.
2. Vidal Lancis C, Martínez-Sánchez JM, Mateos Mazón M, Peris Tuser M. Breast cancer mortality trend in Spain and its Autonomous Communities during the period 190-2005. (Mortalidad por cáncer de mama: evolución en España y sus comunidades autónomas durante el período 1980-2005). Rev Esp Salud Publica 2010, 84:53-59. 10.1590/S1135-57272010000100006, 20376413.
3. Jones SE, Moon T, Bonadonna G, Valagussa P, Rivkin S, Buzdar A, Montague E, Powles T. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a Natural History Data Base. Am J Clin Oncol 1987, 5:387-395.
4. Leone BA, Romero A, Rabinvich MG, Vallejo CT, Bianco A, Perez JE, Machiavelli M, Rodriguez R, Alvarez LA. Stage IV breast cancer: clinical course and survival of patients with osseous versus extraosseous metastases at initial diagnosis. The GOCS (Grupo Oncológico Cooperativo del Sur) experience. Am J Clin Oncol 1988, 11:618-622. 10.1097/00000421-198812000-00004, 3055932.
5. Rosen PR, Groshen S, Saigo PE, Hinne DW, Hellman S. A long term follow-up study of survival in stage I (T1N0M0) breast carcinoma. J Clin Oncol 1989, 7:355-366.
6. Landys K, Persson S, Kovarik J, Hultborn R, Holmerg E. Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: Results of a 20-year median follow-up. Breast Cancer Res Treat 1998, 49:27-33. 10.1023/A:1005980919916, 9694608.
7. Molino A, Pelosi G, Micciolo R, Turazza M, Nortilli R, Pavanel F, Cetto GL. Bone marrow micrometastases in breast cancer patients. Breast Cancer Res Treat 1999, 58:123-130. 10.1023/A:1006336100142, 10674876.
8. Mansi JL, Gogas H, Bliss J, Gazet JC, Berger U, Coombes RC. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 1999, 354:197-202. 10.1016/S0140-6736(98)10175-7, 10421301.
9. Redding WH, Combes RC, Monaghan P, Clink HM, Imrie SF, Dearnaley DP, Sloane JP, Powles TJ, Neville AM. Detection of micrometastases in patients with primary breast cancer. Lancet 1983, 2:1271-1274.
10. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
11. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
12. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11:5678-5685. 10.1158/1078-0432.CCR-04-2421, 16115903.
13. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J Clin Oncol 2005, 23:7350-7360. 10.1200/JCO.2005.03.3845, 16145060.
14. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502. 10.1001/jama.295.21.2492, 16757721.
15. Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad O, Diel I, Solomayer EF, Theocharous P, Coombes RC, Smith BM, Wunder E, Marolleau JP, Garcia J, Pantel K. Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. Establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1999, 1:377-388. 10.1080/0032472031000141283, 20426539.
16. Goldhirsch A, Wood WC, Gelber RD, Thürlimann B, Senn HJ. Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer. J Clin Oncol 2003, 21:3357-3365. 10.1200/JCO.2003.04.576, 12847142.
17. Fraile M, Solà M, Alberro A, Santesteban P, Ramos M, Fábregas R, Gubern JM, Culell P, Vidal-Sicart S, Solsona J, Mora A, Veloso E, Deulofeu P, Janer J, Ballester B, Puig P, Acea B, de Pablo JL. Linfadenectomía axilar completa frente a observación en pacientes con micrometástasis en el ganglio centinela por neoplasia de mama. Resultados preliminares del ensayo clínico multicéntrico. Rev Senol Patol Mam 2006, 19:17-22.
18. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Süto{double acute} T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD, . for the Herceptin Adjuvant (HERA) Trial Study Team Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N Engl J Med 2005, 353:1659-1672. 10.1056/NEJMoa052306, 16236737, for the Herceptin Adjuvant (HERA) Trial Study Team.
19. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh L, Vogel VG, Visscher D W, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. N Engl J Med 2005, 353:1673-1684. 10.1056/NEJMoa052122, 16236738.
20. Hortobagyi GN. Trastuzumab in the Treatment of Breast Cancer. N Engl J Med 2005, 353:1734-1736. 10.1056/NEJMe058196, 16236745.
21. Naume B, Borgen E, Kvalheim G, Karesen R, Qvist H, Sauer T, Kumar T, Nesland J. Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics. Clin Cancer Res 2001, 7:4122-4129.
22. Fetsch P, Cowan KH, Weng DE, Freifield A, Filie AC, Abati A. Detection of circulating tumor cells and micrometastases in stage II, III and IV breast cancer patients utilizing cytology and immunocytochemistry. Diagn Cytopathol 2000, 22:323-328. 10.1002/(SICI)1097-0339(200005)22:5<323::AID-DC13>3.0.CO;2-L, 10790242.
23. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes C, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K. A pooled analysis of bone marrow micrometastasis in breast cancer. N EnglJ Med 2005, 353:793-802.
24. Diel IJ, Kaufman M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, Kaul S, Bastert G. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996, 88:1652-1658. 10.1093/jnci/88.22.1652, 8931609.
25. Janni W, Gastroph S, Hepp F, Kentenich C, Rjosk D, Dimpfl T, Sommer H, Braun S. Prognostic significance of an increased number of micrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma. Cancer 2000, 88:2252-2259. 10.1002/(SICI)1097-0142(20000515)88:10<2252::AID-CNCR8>3.0.CO;2-Q, 10820346.
26. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmüller G, Schlimok G. Cytokeratin-positive cells in the bone marrow and survival of patients in stage I, II or III breast cancer. N Engl J Med 2000, 342:525-533. 10.1056/NEJM200002243420801, 10684910.
27. Braun S, Cevatli BS, Assemi C, Janni W, Kentenich CRM, Schindlbeck C, Rjosk D, Hepp F. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J Clin Oncol 2001, 19:1468-1475.
28. García MT. Efficacy of chemotherapy on the elimination of tumor cells in bone marrow hidden in patients with breast cancer. Relationship of tumor cells in bone marrow with evolving forms of the disease. PhD Thesis 2001, University of Valencia: Oncology Department.
29. Naume B, Borgen E, Beiske K, Herstad TK, Ravnås G, Renolen A, Trachsel S, Thrane-Steen K, Funderud S, Kvalheim G. Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood. Hematother 1997, 6:103-114.
30. Zach O, Lutz D. Tumor cell detection in peripheral blood and bone marrow. Curr Opin Oncol 2006, 18:48-56. 10.1097/01.cco.0000198973.51615.fa, 16357564.
31. Stathopoulos EN, Sanidas E, Kafousi M, Mavroudis D, Askoxylakis J, Bozionelou V, Perraki M, Tsiftsis D, Georgoulias V. Detection of CK-19 mRNA positive cells in peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. Ann Oncol 2005, 16:240-246. 10.1093/annonc/mdi043, 15668277.
32. Fabisiewicz A, Kulik J, Kober P, Brewczyńska E, Pieńkowski T, Siedlecki JA. Detection of circulating breast cancer cells in peripheral blood by a two-marker reverse transcriptase-polymerase chain reaction assay. Acta Biochemin Polonica 2004, 51:747-755.
33. Weinschenker P, Prado Soares H, Clark O, del Giglio A. Immunocytochemical detection of epithelial cells in the bone marrow of primary breast cancer patients: a meta-analysis. Breast Cancer Res Treat 2004, 87:215-224. 10.1007/s10549-004-8691-1, 15528964.
34. Gerber B, Krause A, Muller H, Richter D, Reimer T, Makovitzky J, Herrnring C, Jeschke U, Kundt G, Friese K. Simultaneous immunohistochemical detection of tumor cells lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol 2001, 19:960-971.
35. Langer I, Guller U, Koechli OR, Berclaz G, Singer G, Schaer G, Fehr MK, Hess T, Oertli D, Bronz L, Schnarwyler B, Wight E, Uehlinger U, Infanger E, Burger D, Zuber M, . Swiss Multicenter Sentinel Lymph Node Study Group in Breast Cancer Association of the presence of bone marrow micrometastases with the sentinel lymph node status in 410 early stage breast cancer patients: results of the Swiss Multicenter Study. Ann Surg Oncol 2007, 14:1896-903. 10.1245/s10434-006-9193-7, 17356955, Swiss Multicenter Sentinel Lymph Node Study Group in Breast Cancer.
36. Cote R, Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, Reintgen DS, Morrow M, Leitch AM, Hunt K. ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer. J Clin Oncol 2010, 28(18 Suppl):CRA504.